Apremilast for Erythema Multiforme

Erythema Multiforme Clinical Trial

— AEM  

Official title:

Apremilast for the Treatment of Refractory Erythema Multiforme

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05875714
• Other study ID #: 842831
• Status: Recruiting
• Phase: Phase 2
• Start date: January 13, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2023
• Source: University of Pennsylvania
• Contact: Joshua S Bryer, BA
• Phone: 215-662-6597
• Email: jbryer[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is recruiting patients with chronic, treatment resistant erythema multiforme (EM), which is a disease that can affect the skin and mucous membranes (mucocutaneous). EM often impacts quality of life with pain, anorexia, hospitalization, and related long-term issues. While there are medications used to treat EM, no single therapeutic agent has been consistently effective for long-term management of disease. Apremilast (trade name: Otezla) is approved to treat Bechet's Disease, a different but similar mucocutaneous disease. In this study, eligible patients will receive apremilast for 6 months of treatment so we can evaluate if there is a difference in pain and the number of EM flares compared to prior to treatment with apremilast.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: December 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study:

1. Presence of oral, genital, or cutaneous erythema multiforme (EM) diagnosed or confirmed by a dermatologist based on clinical and/or histopathologic data.

2. EM must be recurrent, defined as having =>2 flares in the six months prior to enrollment (or =>4 flares in the year prior to enrollment).

3. EM must be refractory to standard therapy defined as 3-month treatment course with valacyclovir and/or a systemic immunomodulatory therapy such as colchicine, dapsone, azathioprine, mycophenolate mofetil, or methotrexate.

4. Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).

5. Willing and able to provide personally signed and dated informed consent form.

6. Stated willingness and ability to comply with all study procedures including adhering to oral apremilast regimen and availability for the duration of the study.

7. Adults aged 18-89 years old.

8. People of childbearing potential (PCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, PCBP who engage in activity by which conception is possible must use one of the approved contraceptive options described below: Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: External or internal condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide. NOTE: This criterion is satisfied as "not applicable" (N/A) for those who practice abstinence as part of their usual and customary way of life, so long as this is maintained throughout study period plus 28 days post-treatment; are postmenopausal; or are of male sex/assigned male at birth (AMAB). Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

1. Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinological, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.

2. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if they were to participate in the study.

3. Prior history of unmanaged depressive symptoms, suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.

4. A score of 4 or higher on Patient Health Questionnaire at screening.

5. Pregnant or breast feeding.

6. Active substance abuse or a history of substance abuse within 6 months prior to Screening.

7. Malignancy or history of malignancy, except for:

1. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;

2. treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.

8. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).

9. Prior treatment with apremilast.

10. Patient unable to comply with study or conform to treatment diary or regular follow up visits.

11. Patients with ocular EM.

12. Concomitant use of immunosuppressive medications for treatment of other diseases.

13. Patients with contraindications to Apremilast according to package insert.

Related Conditions & MeSH terms

• Erythema
• Erythema Multiforme

Intervention

Drug:
• Apremilast
Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily

Locations

Country	Name	City	State
United States	Perelman Center For Advanced Medicine	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Robert Micheletti

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	EM flares on medication	Change in frequency and duration of EM flares at 24-week evaluation.	24 weeks
Secondary	Pain on medication	Change in pain severity (on 0 to 10 scale) of EM flares at 24-week evaluation	24 weeks
Secondary	Flares off medication	Change in frequency and duration of flares at 36-week follow-up.	36 weeks
Secondary	Pain off medication	Change in pain severity (on 0-10 visual analogue scale) of EM flares at 36-week follow-up.	36 weeks
Secondary	Prednisone	Use of prednisone as rescue therapy to treat flares.	36 weeks